New vaccine brings hope to north Cameroon

A project in Cameroon’s drought-stricken northern region is enabling an increasing number of farmers to take up traditional poultry keeping. In the villages of Bibemi and Djola in Garoua, regular access to the I-2 Newcastle Disease (ND) vaccine is protecting poultry against this fatal disease, and is providing farmers with a complimentary source of income in the face of an erratic climate and dwindling crop yields.

The campaign is run by CAPHAVET, a society of veterinarians in Cameroon, with support from the Global Alliance for Livestock Veterinary Medicine (GALVmed) – a non-profit company that makes livestock vaccines accessible and affordable to smallholder farmers in Africa and South Asia. CAPHAVET distributes ND vaccinations to poultry keepers every 4 months. According to GALVmed’s poultry project manager, Jean-Narcisse Koffi, “GALVmed has continued to multiply its efforts working with partners on the ground to help smallholder farmers combat this infection, which can kill over 80-90% of poultry.”

Direct and indirect impacts

Hebena Brigitte, a farmer from the Djola village says the programme is improving farmers’ incomes and the wellbeing of their families. “From the sale of my chickens, I am now able to pay my children’s school fees and medical bills. Before, due to the prolonged drought, poor harvests from my vegetable farm left us desperate.”

In the Bibeni village where the project was introduced 2 years ago, farmers are also benefiting from the boost in poultry production. “I rear over 600 chickens and sell about 200 every month. I am also able to sell 10-15 trays of 24 eggs a week. I sold far less when there was no modern vaccine,” says local farmer Kangoube Joel.

Farmers are seeing indirect benefits to vaccinated chickens, which some are saying are at healthier weights and achieving higher market prices. “Before the programme, my chickens weighed less than 2.5 kg, but now, thanks to the vaccine, they weigh about 5 kg when they are ready for market,” attests Joel. At 4-6 months, vaccinated chickens weigh 4-5 kg and sell for between 4,000-6,000 Central African francs (XAF) (US $6-8), while a tray of 24 eggs sells at 1,200 XFA (US $2). Prior to the vaccine, Joel’s chickens sold for between 2,500-3,000 XFA (US $4.06-4.87).

Partner veterinarians from Garoua say more emphasis should be placed on farmer sensitisation to vaccine benefits and broadening vaccine distribution. Habiba Hayatou, a female farmer at Bibemi village says some of her neighbours who weren’t aware of the project initially resisted vaccinating their birds, and suffered heavy losses when the infection broke out. “I vaccinated all my 250 chickens a month before the infection was announced, which is why they all survived,” says Hayatou.

Local health service support

According to Dr Mahamat Mamate, project manager at CAPHAVET in Ngoundere, since 2013, the vaccination programme has been introduced to poultry farmers in the far north, north, northwest and western regions of Cameroon. This has been achieved partly through the continuous training of local vaccinators. Although not veterinary experts, the vaccinators, who are trained by CAPHAVET and Cameroon’s cotton production health service SODECOTON, advise poultry keepers on disease preventive measures. SODECOTON supports smallholder cotton farmers in the area with alternative income generating activities as part of their corporate social responsibility. In the Garoua region alone, over 100 vaccinators have been trained on providing poultry management advice in the local language of Fulfude.

Dr Assana Mouhamadou, the chief of service for veterinary medicine at SODECOTON and coordinator of vaccinator training, says that as well as helping smallholder farmers, these youths earn some additional income through their work. Trained vaccinators purchase vials from SODECOTON containing 50 doses of the vaccine for 2,500 XFA (US $4.06) and administer one dose per chicken for small communities of 15-20 households. In less than five hours, they can administer the vaccine to over 15 households in small villages. The vaccinator receives a contribution of roughly 3,500 XAF (US $5) from each community they deliver the vaccination to.

Upping the uptake

The vaccinating process is simple to understand says Louablbe Robert, a vaccinator in the Pitoa community.
It involves mixing 4 ml of water in a bottle of 5 ml I-2 ND vaccine, which contains 50 doses. Robert vaccinated 700 chickens from 46 households in 2015 and says this number doubled in 2016, indicating that many more families are responding positively to the new vaccine. Bouba Thomas, another vaccinator, points out that the simplicity of the new eye drop procedure is encouraging more farmers to use it. “Even farmers who used to refuse the [former injection] vaccination accept the new method,” he says. The Itanew and Multi-vax injections used 3 years ago were difficult for the local agents to administer and could not be used on chicks. However, the new application is showing positive results for the farmers, explains Dr. Mouhamadou.

ND vaccines are also supplied to commercial chicken farmers in greater volumes to cater for large-scale production of over 1,000 chickens, says Dr Azibe Mazra, CAPHAVET Director General.
But for traditional, backyard poultry farming, where fewer than 200 chickens are reared for subsistence purposes, the smaller package of I-2 is provided. “We supply the smaller packs to remote village areas, with poor road networks, experiencing problems with the infection,” explains Mazra. Over 1.5 million chickens now receive the I-2 ND vaccine every 4 months in the north regions of Cameroon since it was introduced 2 years ago, according to Azibe. And with the intensification of the campaign through increased vaccinator training and sensitisation of many more households to poultry farming, vaccination uptake shows signs of increasing.

Written by Elias Ntungwe Ngalame, WRENmedia consultant

Researchers on a mission to improve the East Coast Fever vaccine

GALVmed recently held a workshop Nairobi (19-20 January 2017) to discuss ongoing research to improve the East Coast Fever (ECF) vaccine. The vaccine, commonly known as Infection and Treatment Method (ITM)  was developed in mid-70s and since then new tools have been developed   to characterise the vaccine strains/stocks and provide new knowledge to make it more efficacious , widely available and to cater to the needs of smallholder farmers in different geographical areas.

While the efficacy of the vaccine is in no doubt, the current ECF-ITM vaccine has a number of drawbacks.  The main drawbacks are related to strain/stock specific immunity, dose packages, administration of the vaccine and cost of vaccine delivery. The strain/stock specific immunity limits its use in some of the endemic countries, particularly in those where the vaccine has not been introduced before. The current ECF-ITM vaccine comes in a 40 dose straw, which makes it difficult to service farmers who have fewer livestock numbers, for example in the dairy sector where farmers normally keep between 1-5 cows. In addition to the inoculation of a cryopreserved (live) vaccine, the cattle have to be administered with a long acting formulation of oxytetracycline antibiotic, which raises the cost of the vaccination.

Researchers have been working to find new technologies that can resolve these challenges and lead to the formulation of an effective live vaccine against the killer disease. The intention of this workshop was therefore to bring together a group of researchers working on the characterisation of the different field strains to review ongoing work and identify new or additional tools that could be used to generate new knowledge in a shorter time frame, leading to formulation of a more effective vaccine against East Coast Fever.  In addition, knowledge emanating from the characterization will equip the decision makers in the new areas with the necessary technical information that will enable them to make decisions on the introduction of the Muguga Cocktail in their countries.

The workshop was attended by molecular biologists and experts in East Coast Fever/Theileria parva (which is the parasite that causes ECF) from GALVmed, International Livestock Research Institute (ILRI), University of Zambia (UNZA), Rwanda, Burundi, Democratic Republic of Congo, South Sudan, Kenya, Uganda and Tanzania.

A number of research papers were presented and debated as the researchers sought to consolidate new knowledge and harmonise their research activities.

“At the moment, we have a number of researchers working on various tools and technologies to characterise the different strains of the ECF vaccine and we would like to see more harmonisation of activities and constant communication across the countries so that we can ensure the appropriate alignment of vaccine and field strains in the manufacturing of the ECF-ITM vaccine,” said Prof. Tony Musoke, GALVmed’s Consultant on East Coast fever vaccine and the organiser of the meeting.

Written by: Beatrice Ouma, GALVmed’s Communications Manager

Further reading

Abstracts Characterisation of Theileria parva strains

Recommendations from Workshop on Molecular Characterisation of Theileria Isolates

Chromosome map of ECF markers

Theileria Parva Satellite Markers and Antigen Primers

Improving poultry productivity in Nigeria

Since July 2016, smallholder farmers in Oyo, Osun and Ogun states in southwest Nigeria have benefited from Newcastle Disease (ND) I-2 poultry vaccination and deworming. Already, the treatment is unlocking the economic potential of poultry production and improving the livelihoods of smallholder farmers.

Initiated by the Global Alliance for Livestock Veterinary Medicines (GALVmed) – a non-profit organisation improving smallholders’ access to livestock vaccines in developing countries – the project was launched to control this highly contagious and lethal infection. Devastating for farmers, ND can kill 80-90% of infected birds. “The aim of the project is to develop sustainable smallholder poultry production in rural communities for improved livelihoods,” says Dr. Samuel Adediran, GALVmed Assistant Director for Market Development and Access.

Positive partnerships

John Olugbohunmi holding a client’s turkey that was wandering into the bush.

Through GALVmed’s Nigerian partner in project delivery, Bdellium Consult, young people are trained as Community Poultry Agents (CPAs). Providing rural smallholder poultry keepers with information on improved poultry management, vaccination and deworming at an affordable cost, enables CPAs to earn a living while contributing to the improved economic wellbeing and livelihood of smallholder farmers.

Morufat Adedeji, a young mother in Osun state has meaningfully increased her income since becoming a CPA in 2016. She says, “On August 8th, I participated in GALVmed training to become a vaccinator and started enjoying the benefits of the new business immediately. I encouraged a farmer with about 15 birds to vaccinate her flock and after three days, she excitedly told me she had started seeing the positive results of the vaccination and gave me a gift of a grown live chicken.” Having carried out over 1,500 vaccinations in four months at 20 naira (US $0.06) per dose, Adedeji has realised a profit of at least 30,000 naira (US $95) from vaccinations alone. “I have been getting phone calls from people I don’t know, asking me to come and vaccinate their birds. More farmers are now vaccinating and deworming their poultry.”

Another CPA, John Olugbohunmi, is an Ordinary National Diploma graduate in pharmaceutical technology who vaccinated about 500 birds in the last four months of 2016. He purchases vials, each one containing 50 doses, and sells a dose for 10 naira (US $0.03) each. After deducting purchasing costs, he makes a profit of about 250 naira (US $0.79) per vial. John says the CPA work has also provided him with extensive information on poultry keeping, enabling him to educate his clients and consider starting up his own poultry business as an additional form of income.

Spreading the word

Adedeji currently administers around 400 vaccinations and 270 dewormings on average per month, but plans to increase sensitisation of the project to poultry keepers in surrounding towns. The target is to sell 2,500 vaccine doses per month but, with referrals mostly disseminated via word of mouth, further resources are required. “I inform people generally about the programme, but would need more posters and flyers to paste so I can distribute the message further and increase awareness,” says Adedeji.

Lack of awareness is also a problem in Oyo state where Olugbohunmi operates. The free range system practised in this area means poultry wander freely and eat what they can find. Often, the poultry keepers operate a minimum input system with little or no feeding to supplement the fowls’ diets. Mindful of these challenges, Olugbohunmi is intensifying sensitisation on best practices in poultry keeping in addition to promoting ND I-2 vaccination and deworming.

Morufat Adedeji vaccinating poultry.

Saving village chickens

One poultry keeper whose 35-bird flock was vaccinated by Adedeji is Rachel Oyebamiji, a tailor and mother of six. Oyebamiji says, “I need the proceeds from selling live chickens to pay my children’s school fees. After my fowls were vaccinated in August, there have been no deaths, no sickness, and they have all grown so big. I also feed my family with some of the eggs and chickens.” Explaining her previous dilemma, she continues, “In 2015, I had 25 birds and about 10 died before I could sell them. The money was barely enough to pay my bills. But since I started using the ND vaccination, none of my fowls have died.”

The vision for the vaccine

According to Dr. Adediran of GALVmed, poultry keeping is an untapped resource that can generate employment for young people in rural and peri-urban areas. “GALVmed supports partners like Bdellium to promote awareness and set-up market networks which facilitate sustainable and affordable access to these and other products for improved livestock health and production,” says Adediran.

The project with Bdellium is GALVmed’s first entry into vaccine delivery in Nigeria, but the overall vision is to make the ND I-2 vaccine for ND control a routine practice among smallholder poultry producers, globally.

Article and photos by Oluyinka Alawode, WRENmedia correspondent

A step closer to treating nagana

Animal African Trypanosomiasis (AAT), or nagana as it is widely known in Africa, is a disease of vertebrate animals that is endemic in 40 African countries. Trypanosome parasites that affect cattle account for up to a 50 percent loss in milk and meat production across the continent. In infected animals, the mortality rate can reach 50-100% within months after exposure, particularly when poor nutrition or other factors contribute to debilitation. Trypanosomiasis is also a major cause of reduced draught power for agricultural production. With all these factors taken into consideration, the total annual cost resulting from the disease is estimated to be US $628 million.

AAT is transmitted by tsetse flies, which can be controlled by traps and insecticides. Infected cattle can also be treated with drugs but increasing drug resistance is becoming a concern. Developing drugs for neglected tropical diseases is a complex and risky process due to high failure rates and excessive costs associated with research, development and clinical studies. However, a potential new trypanocide (a drug used to kill or control a single-celled parasite) to treat cattle is undergoing early development by a major biopharmaceutical company. The identification and commercial development of a trypanocidal agent is a huge step forward in the progress towards controlling this deadly disease, which would prove highly significant for millions of smallholder farmers and for Africa’s economy.

Overcoming the obstacles

Throughout Africa, with few exceptions, governments lack the necessary resources to provide effective veterinary services to control nagana. The present priority in Africa is to promote agricultural production by applying knowledge and methods that are already available. Drugs to treat livestock infected with AAT do exist, but introduced over 40 years ago, these treatments are now outdated with under strength compounds to which the disease is resistant. “An effective treatment for AAT would be fantastic for farmers. It would mean with just one injection, animals could be free from infection for years or for a lifetime,” says Dr Rosemary Peter, Programme Manager for AAT at the Global Alliance for Livestock Veterinary Medicines (GALVmed).

the total annual cost resulting from the disease is estimated to be US $628 million.

A significant hurdle to AAT treatment development is the lack of incentive for pharmaceutical companies, who may not receive a sufficient return on their investment. “Trypanosomiasis is not a blockbuster disease from which large companies can achieve a significant profit – as a purely African disease, the ability to achieve sales worldwide is limited,” states Peter. To counter the growing problem of substandard drugs and garner interest in trypanocide development, GALVmed, a not-for-profit company that makes livestock vaccines accessible to smallholder farmers, issued a competitive call to their network of partners with pharmaceutical development experience and those with an interest in developing products for Africa. Novel drugs were tested for their efficacy against the two predominant parasite species that cause AA T – Trypanosoma congolense and T. vivax.

One major challenge to identifying a potential trypanocidal candidate was finding an effective drug. “It is difficult to find compounds that will work as very little is understood about the trypanosome parasite and the cell biology of each stage differentiation,” says Peter. However, a potential trypanocidal drug that closely fits the requirements of the Target Product Profile (the ‘wants’ and ‘musts’ of an intended commercial therapeutic, i.e. the ability to treat the target species) has been identified. The potential candidate is about to enter the final stages of testing by GALVmed’s pharmaceutical partner, Anacor.

Diagnostic project partnerships

The difficulty in diagnosing trypanosomiasis is another hindrance to its management. Not only are there no specific clinical signs but when looking to diagnose the disease, it is difficult to find parasites in infected animals’ blood (as there are generally not a lot). The only way to confirm a diagnosis in affected animals is to demonstrate and identify the parasites in body fluids. To develop a simple and effective trypanosomiasis field diagnostic test GALVmed has worked in partnership with the University of Dundee. Taking a hi-tech approach, the university research team identified the components of T. vivax, a strain which stimulates antibody production in cattle. One of these components was then used to develop into a prototype diagnostic device. This was achieved in collaboration with BBI Solutions OEM Limited, who specialise in immunoassay development which detects and measures specific proteins or other substances through their properties as antigens or antibodies. As a result of this collaboration, a simple AAT test has successfully been developed that can be used in the remote settings of rural Africa, without the need for electricity or any additional equipment.

Photo credit: University of Dundee

From a single drop of blood, farmers will be able to use the AAT test to detect, within 30 minutes, whether the animal is infected with the parasite T. vivax. A positive result indicates the presence of the disease aiding smallholders in the timely treatment of their livestock. The diagnostic is currently being tested in African labs to see how it performs.

Dr Jeremy Salt, Senior Director of Research and Development at GALVmed said,

“Such a test could allow millions of smallholder farmers an efficient way to test their cattle for this debilitating disease and give peace of mind that any subsequent treatment for T. vivax infection will be done with the certainty that the animal is infected, which saves the farmer money. This will give more control to the smallholder farmers whose quality of life has been affected by this disease that covers over 10 million square kilometres of Africa. To ensure that the final test is widely used throughout the regions where it’s endemic, GALVmed will be working with scientists, manufacturers and distributors in the 40 countries where AAT is rife to create a sustainable supply chain for the final product.”

Written by Sophie Reeve, WRENmedia

Tackling the major cause of epilepsy in the developing world

Porcine cysticercosis is a zoonotic disease, which can lead to epilepsy in humans. A new vaccine and dewormer have been registered to counter the disease in pigs thereby stopping the cycle of transmission to humans. In Udaipur, Nepal, where vaccination projects were initiated, pig farmers are hopeful that not only will the vaccine and dewormer improve their health but also their economic outlook as pigs become healthier and sell for more.

The vaccine was developed by Professor Marshall Lightowlers of the University of Melbourne and is being distributed by our partner Indian Immunologicals Ltd. The dewormer is manufactured by our partner MCI Sante Animale in Morocco.

Further reading: First ever licenced vaccine against major cause of epilepsy in developing world

Bringing the benefits of the ECF vaccine to Rwandan farmers

Rwandan farmers will soon have a reason to smile as they will be able to protect their cattle from one of the deadliest cattle diseases – East Coast Fever. The disease that kills numerous cattle across the East Africa region is present in most regions of Rwanda and yet unlike their East African counterparts, Rwandan farmers have not been benefiting from a vital vaccine that could protect their cattle and reduce their losses to the disease.

During a workshop held in early December 2016 in Kigali to validate an ECF-ITM Muguga Cocktail field trial in the country, it emerged that successful control of the disease was seen using the Muguga Cocktail, which provides a one shot immunity for the life of the cow. Over 65 participants attended the workshop from all regions across Rwanda and interest in the vaccine, particularly from farmers present, was immense.

In the course of 2016, GALVmed has been working with the Rwanda Agricultural Board (RAB) and the Department of Veterinary Services to conduct a controlled study using the Muguga Cocktail vaccine. “Our tests have proved that the Muguga Cocktail vaccine currently being used across East Africa can provide cross immunity against the circulating Rwandan field strains in this study. This is a positive result, a step in the right direction towards bringing the benefits of this vaccine to farmers in Rwanda,” said Jeremy Salt, GALVmed’s Director for Research & Development.

For GALVmed, it is important that this vaccine is made available in Rwanda to control ECF and the resultant losses and cattle deaths being incurred by smallholder farmers.

Current control measures not very effective

Current control methods of ECF in Rwanda include spraying cattle with acaricides to control ticks and treatment of cattle infected with the parasite. However, these are not usually reliable as the drugs of choice to treat the disease are only effective if treatment is started early and can be very expensive. Besides, ticks have been observed to be developing resistance to acaricides in use and the drugs used in cattle are becoming increasingly ineffective due to the development of resistance and the availability of poor or counterfeit products. Hence, the need to have a safer and effective disease control strategy using the vaccine.

Moving forward

Before large-scale vaccination can begin, there is a need to set up a structure that will enhance vaccine uptake country-wide. This will include training of trainers and vaccinators as well as conducting awareness campaigns in all regions of the country to enable the farmers understand the benefit of the vaccine.

During the workshop, it was acknowledged that there is need for market study trials in all regions of Rwanda and in the next couple of months there will be targeted immunisation of up to 300 cattle and a vibrant monitoring system put in place to obtain feedback and to ensure safe usage of the vaccine.

By Beatrice Ouma, GALVmed’s Communications Manager

Fulani freed from the threat of PPR and SGP in Mali

Peste des Petits Ruminants (PPR) and Sheep and Goat Pox (SGP) result in major losses in livestock productivity and also death of many small ruminants for farmers in Safèbougou, a Malian village located about 100 km north of Bamako. “Every year, there were cases of sheep pox and PPR,” says Boubacar Dramane Bah, a 65 year old Fulani livestock farmer, standing in the middle of his goat herd. “PPR is a dangerous disease. We know when they are infected, the sick animals cry and, after only two days, they
die,” continues Bah.

PPR and SGP have been recurrent diseases, not just in the region but across Mali where it devastates the local economy which is dependent on livestock. In the Malian Bambara language, the name for PPR is Berebla meaning ‘end of career’. This is due to the high mortality rate during an outbreak, which according to the World Organisation for Animal Health (OIE), is between 90-100%. PPR can also cause abortion in female animals. SGP has a slightly lower mortality rate of between 70-90% but also causes huge economic losses resulting from decreased milk production as well as reduced quality of hides and wool.

Vaccines for both PPR and SGP are available separately, but their use has been predominantly limited to government vaccination campaigns once an outbreak occurs, which sometimes may be too late for affected communities. Non-profit company, the Global Alliance for Livestock Veterinary Medicines (GALVmed) has been supporting Morocco-based pharmaceutical company, MCI Santé Animale, to trial vaccinations using LYOPOX-PPR (a combined vaccine against both diseases) along with deworming of sheep and goats. With this new combined vaccine, farmers are able to actively manage their livestock’s health by vaccinating against both diseases before an outbreak occurs.

In Safèbougou, houses built of mud bricks dot the land owned by the Fulani – an ethnic pastoralist group whose livestock are passed from father to son. “We live only from the livestock that our parents bequeathed us,” says Bah. Each member of his family (adult men and women) has around 80 goats and sheep. With his family comprising of 10 people, they have around 800 goats and sheep in total.

For these livestock farmers, small ruminants are a critical source of income so the impact of these diseases can be economically devastating. According to Bah, when he sells a goat or a sheep, he can earn XOF 60,000 (about US $100), a sum that is sufficient to cover the monthly expenses of his family.

Until the introduction of this new combined vaccine against SGP and PPR, herders did not vaccinate their animals because of the cost. “For 20 years I have been working with livestock farmers from surrounding villages,” says Aguibou Sylla, the Sirakorola village veterinarian. “For the first time, the farmers have taken the initiative to request this new vaccine.” Sylla is one of the vets who recently took part in the vaccination and deworming project. “We received 10,000 doses of the vaccine and selected 14 surrounding villages to participate in the project, where we vaccinated all small ruminants,” states Sylla.

Bah is pleased with the recent vaccinations in his village. “There are a lot of Fulani herders in the surrounding villages, but since the animals were vaccinated, no one has told me of a single case of PPR or sheep pox,” Bah says. “One year I lost all my animals due to PPR, but the arrival of this new vaccine [LYOPOX-PPR] has saved
my flock so far.”

The vaccinators are also confident that the new vaccine does not result in any common complications in animals, such as abortion in pregnant females. The results of laboratory analysis of blood samples taken from vaccinated animals confirm the livestock farmers’ observations of the efficacy of LYOPOX-PPR. In total, more than 95,000 small ruminants were vaccinated during the project in three regions of Mali: Kayes, Sikasso and Koulikoro.

Dr Moussa Keita, who supervised the vaccination programme in Mali, states that the vaccine is efficient and cost-effective as both diseases are controlled at the same time. The trial found that smallholder herders are willing to pay for this vaccination that was previously provided by the government for free. Further data provided by the trial (which was approved by the regulatory authorities) will also support the vaccine licensing (registration) process in the West African Economic and Monetary Union (UEMOA), which covers 14 countries including Mali. MCI Santé Animale has filed the vaccine registration of LYOPOX-PPR with the UEMOA and when registration is complete the vaccine will be available for all countries in the UEMOA region.

Written by: Soumaila T. Diarra, WRENmedia correspondent

Produced by WRENmedia for GALVmed

 

 

East Coast Fever training curriculum and manual for vaccinators

East Coast Fever (ECF) is a serious, often fatal, disease of cattle that causes major economic losses across 11 countries in eastern, central and southern Africa. Caused by single-celled parasite, the disease is transmitted by the brown ear tick, which is found in hay or standing grass. ECF is a significant constraint to livestock farmers in affected countries with one animal being lost every 30 seconds and more than 25 million cattle at risk.

ECF can be prevented by using the Muguga Cocktail vaccine, which is manufactured by the Centre for Ticks and Tick-Borne Diseases in Malawi and distributed by local companies, Ronheim and PharmaVax in Tanzania.

GALVmed – a not-for-profit company that makes livestock vaccines accessible to smallholder farmers – and its partners has launched an initiative to standardise training provided to ECF vaccinators. A standardised training curriculum and manual originally developed by Kenya Agricultural Research Institute, and later with input from the International Livestock Research Institute, GALVmed and Tanzanian stakeholders including the Directorate of Veterinary Services, the Veterinary Council of Tanzania, and Tanzanian distributors is now being used for the training of ECF vaccinators.

View the podcast’s script here.

Building a strong community animal health care system in rural India

Livestock keepers in rural and tribal areas of Odisha, India are often unaware about deworming, vaccination and other health care concepts to protect their livestock from mortality. Livestock plays a vital role in livelihood security for these rural and tribal populations. Many government and non-governmental organisations are working towards livelihood improvement through livestock in Odisha. There are two major challenges – a lack of trained professionals working in the local animal health care services and limited availability of affordable products in tribal areas.

To address these challenges, the Global Alliance for Livestock Veterinary Medicines (GALVmed) has partnered with the western India-based Hester Biosciences Limited  to develop and distribute customised livestock vaccines and health care products to rural areas of Odisha. To strengthen animal health care services with quality community animal health workers, GALVmed-Hester has collaborated with the Professional Assistance for Development Action (PRADAN) and Pathe Pathsahala in Odisha.

Each partner plays a crucial role in increasing the distribution of animal health care products throughout Odisha. The availability of vaccines and animal health products is ensured by the establishment of an efficient supply chain and a dedicated sales team at the biotech company, Hester Biosciences Limited.

PRADAN, a voluntary organisation that works to promote and strengthen livelihoods for the rural poor, selects the community animal health workers, raises awareness  of vaccination and improved management practices of backyard poultry and small ruminants, as well as vaccination and service delivery in five districts of Odisha (Koraput, Rayagada, Kalahandi, Kandhamal and Anugul).

Pathe Pathshala provides professional development training for the community animal health workers. The organisation conducts classes on a variety of farm and rural community skills for farmers, pastoralists, students and women, at their place, in their time and in their language to ease their daily toil.

Since June 2016, 106 community animal health workers (CAHW) have been trained – the majority, 99, who are women. Through this partnership, 21,994 backyard poultry have been vaccinated against Newcastle disease, 9,088 goats vaccinated against Peste des petits ruminants and 6,333 goats vaccinated against Goat Pox in rural parts of Odisha. This initial development indicates an exciting future for this project, its partners and above all, the farmers and CAHW who increase their quality of life.

By: Rahul Srivastava, GALVmed’s Marketing Officer for South Asia

Vaccinating chickens leads to better nutrition for communities in Jharkhand, India

For 33 year old Amrita Kunjur, vaccinating her poultry against Newcastle Disease (ND) has brought an added value to her family. Amrita who lives in the rural hinterland of Ranchi, the capital city of Jharkhand state in India, has always owned chickens. But due to the prevalence of Ranikhet Disease (Newcastle Disease), the flock never grew to a large enough size to earn a bit of extra income and for regular consumption.

“Earlier, we would hardly eat chicken regularly. We did not earn enough money to buy chickens,” says Amrita.

Amrita and her family exemplified the general condition of tribal families in Jharkhand. Many of their chickens were being wiped out mainly by ND and hardly had enough chickens to eat, let alone sell. For most of India’s tribal families, agriculture is the primary source of livelihood. But due to long dry spells, farming has not been as productive as desired and they often resort to buying food that they once produced. With inadequate income, most families find it extremely challenging to have proper nutritional intake, especially eggs and chicken. Buying chicken for consumption is not prioritised in comparison to other basic household needs. For families to afford to eat chicken, they must be able to keep free range chicken, free from diseases.

Vaccine leads to better nutrition

With the introduction of the Lasota ND vaccine in 2015, backyard poultry has flourished. Amrita’s family, who only managed to keep up to ten chickens before, have now increased their flock size to nearly fifty. As a result, the family can now afford to consume at least one chicken every week, giving them the much needed protein. Plus, considering the market value of one chicken at INR 300-400 (US$ 4.5 – 6) within the locality, the family is saving about INR 1500 (US$ 23), or about 60 percent of their present monthly food budget.

Another case is that of 32-year old Mariam Karkatta, who owns a flock of about 70 chickens, ten times more than she owned before she started vaccinating her chickens.

Being an early adopter, she was one of the first in her community to embrace the vaccination programme. After experiencing the benefits of vaccination first-hand, she actively promoted the vaccine in her village, which resulted in substantial increase in chicken population.

Consumption increases with growth in chicken flock

While Mariam’s family could only consume a few chickens the whole year previously, consumption has gone up to about two chickens every month.

For Mariam, the main concern has been the nutrition of her children. Apart from serving the children a regular diet of chicken, she also serves them chicken soup when they are ill. Additionally, eggs are added into their diet. “My son used to catch the flu easily but now he is healthy,” she remarks with a smile, pointing to her school-going son.

With the growth of her flock, Mariam keeps a healthy food budget. As she doesn’t have to buy chickens, she spends about INR 4000-5000 (US $ 60 – 75) on food every month.

With more and more families vaccinating their poultry against ND, it is evident that nutritional intake is slowly improving as families are now able to add chicken and eggs to their regular diets. This is a major boost to the health of community members, particularly children. It is a proof that, even supporting one parameter such as vaccination, goes a long way in improving the lives of poor rural families.

Written by Prasenjit De of Alternatives for GALVmed